RBC Capital lowers uniQure price target to $48 after trial misses significance
RBC Capital cut its price target for uniQure (QURE) to $48, down from $65, after four‑year trial data showed a p‑value of 0.144 for the primary endpoint. The stock fell 39% over the past week to $23.37. UniQure reported a second‑quarter loss of $1.22 per share, wider than the $0.84 expected, while revenue rose 9.4% to $5.8 million, beating the $5.49 million forecast. RBC kept its Outperform rating, noting the price target reflects the new outlook.
Why it matters
RBC Capital says the lower target reflects the missed statistical significance, which could keep pressure on the share price. The firm also notes the price target implies a 105.4% upside from the October 1 close, highlighting the stock’s volatility.
Key facts
- 1RBC Capital reduced its price target for uniQure to $48, down from $65. investing.com
- 2The stock fell 39% over the last week to $23.37. investing.com
- 3Four‑year trial data showed a p‑value of 0.144 for the primary cUHDRS endpoint. investing.com
- 4UniQure posted a Q2 adjusted loss of $1.22 per share versus a forecast loss of $0.84 per share. investing.com
- 5Revenue for Q2 was $5.8 million, exceeding estimates of $5.49 million. investing.com
- 6RBC Capital maintained an Outperform rating and a $48 price target, implying a 105.4% upside from the Oct 1 close. tradingview.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.